ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "juvenile idiopathic arthritis (JIA) and methotrexate (MTX)"

  • Abstract Number: 2392 • 2018 ACR/ARHP Annual Meeting

    Are Single Nucleotide Polymorphisms in Methotrexate Transporter Proteins Associated with Methotrexate Intolerance in Juvenile Idiopathic Arthritis?

    Nini Kyvsgaard1, Torben Mikkelsen1, Anne Estmann2, Thomas Als3, Jane Hvarregaard Christensen3, Thomas Corydon3 and Troels Herlin1, 1Pediatric and Adolescent Medicine, Aarhus University Hospital, Aarhus N, Denmark, 2Department of Pediatric Rheumatology, H.C. Andersen's Children's Hospital, Odense, Denmark, 3Department of Biomedicine, Aarhus University, Aarhus C, Denmark

    Background/Purpose: Methotrexate (MTX) intolerance is common in juvenile idiopathic arthritis (JIA) and poses the risk of premature termination of an effective treatment. MTX intolerance is…
  • Abstract Number: 2393 • 2018 ACR/ARHP Annual Meeting

    Is Methotrexate-Induced Nausea in Juvenile Idiopathic Arthritis Influenced By Anxiety or Coping Strategies?

    Nini Kyvsgaard1, Mikael Thastum2, Torben Mikkelsen1, Anne Estmann3 and Troels Herlin1, 1Pediatric and Adolescent Medicine, Aarhus University Hospital, Aarhus N, Denmark, 2Department of Psychology and Behavioural Sciences, Aarhus University, Aarhus C, Denmark, 3Department of Pediatric Rheumatology, H.C. Andersen's Children's Hospital, Odense, Denmark

    Background/Purpose: Nausea to low-dose methotrexate (MTX) is a significant clinical challenge in the treatment of juvenile idiopathic arthritis (JIA). There exists a large inter-individual variation…
  • Abstract Number: 34 • 2017 Pediatric Rheumatology Symposium

    The SLCO1B1 *14 Allele is Associated with Poor Response to Subcutaneous Methotrexate in Patients with Juvenile Idiopathic Arthritis

    Halima Moncrieffe1, Laura B Ramsey2, Marc Sudman3, Beth Gottlieb4, Carl D Langefeld5, Daniel Lovell6, Susan D Thompson7 and JIA Gene Expression Study Consortium, 1Center for Autoimmune Genomics and Etiology and Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Division of Research in Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, 5Department of Biostatistical Sciences and Center for Public Health Genomics, Wake Forest School of Medicine, Winston-Salem, NC, 6Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 7Center for Autoimmune Disease Genomics and Etiology and Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Variants in the SLCO1B1 gene, encoding a hepatic methotrexate (MTX) transporter, affect clearance of high-dose MTX in leukemia patients.  We aimed to assess the…
  • Abstract Number: 3008 • 2016 ACR/ARHP Annual Meeting

    Clinical Factors Associated with Non-Response to Methotrexate in Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis Response to Treatment Consortium

    Sunil Sampath1,2, Jamie C Sergeant1,3, Sebastien Viatte2, Roberto Carrasco1, Joanna Cobb2, Samantha Smith4, Anne Hinks2, Lucy R Wedderburn5,6, Michael W. Beresford7,8, Kimme L. Hyrich1, Wendy Thomson2 and Childhood Arthritis Response to Medication Study,Childhood Arthritis Prospective Study, British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study, Biologics for Children with Rheumatic Diseases Study, 1Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 2Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, 3NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, 4Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Mancherster, United Kingdom, 5Paediatric Rheumatology Department, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, 6Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, 7Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, United Kingdom, 8Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom

    Background/Purpose: Although the recommended first line treatment for JIA, up to 50% of children will not respond to MTX. Currently, it is not possibly to…
  • Abstract Number: 3009 • 2016 ACR/ARHP Annual Meeting

    Safety and Effectiveness of Adalimumab±Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis

    Daniel J Lovell1, Nicola Ruperto2, Carol Wallace1, Mary Toth1, Ivan Foeldvari2, John Bohnsack1, Diana Milojevic1, C. Egla Rabinovich1, Daniel Kingsbury1, Katherine Marzan1, Pierre Quartier3, Kirsten Minden2, Elizabeth Chalom1, Gerd Horneff2, Rolf M. Kuester2, Jason Dare1, Miriam Heinrich4, Hartmut Kupper4, Jasmina Kalabic4, Hermine I. Brunner1, Alberto Martini2 and on behalf of PRINTO and PRCSG, 1PRCSG, Cincinnati, OH, 2PRINTO-IRCCS, Genova, Italy, 3Hopital Necker-Enfants Malades, Paris, France, 4AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

    Background/Purpose:  Juvenile Idiopathic Arthritis (JIA) is the most common chronic inflammatory rheumatic diseases of childhood. Due to their long-term safety and efficacy, biologic disease modifying…
  • Abstract Number: 299 • 2014 ACR/ARHP Annual Meeting

    A Controlled Trial of Intra-Articular Corticosteroids with or without Methotrexate in Oligoarticular Juvenile Idiopathic Arthritis

    Angelo Ravelli1,2, Giulia Bracciolini3, Sergio Davì3, Angela Pistorio4, Alessandro Consolaro4, Sara Verazza3, Bianca Lattanzi4, Giovanni Filocamo4, Sara Dalprà3, Maurizio Gattinara5, Valeria Gerloni6, Antonella Insalaco7, Fabrizio De Benedetti Sr.8, Adele Civino9, Luciana Breda10, Loredana Lepore11, Maria Cristina Maggio12, Franco Garofalo13, Silvia Magni-Manzoni14, Donato Rigante15, Antonella Buoncompagni4, Marco Gattorno4, Clara Malattia16, Stefania Viola17, Paolo Picco4, Nicolino Ruperto18 and Alberto Martini1, 1Istituto Giannina Gaslini and University of Genova, Genova, Italy, 2University of Genova, Genova, Italy, 3Pediatria II, Istituto Giannina Gaslini, Genova, Italy, 4Istituto Giannina Gaslini, Genova, Italy, 5Pediatric Rheumatology, Istituto Ortopedico Gaetano Pini, Milano, Italy, 6Pediatric Rheumatology Unit, Department of Rheumatology, Istituto Ortopedico Gaetano Pini, Milano, Italy, 7Department of Pediatric Medicine,, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 8Clinica Pediatrica, Ospedale Pediatrico Bambino Gesù, Roma, Italy, 9Ospedale Cardinale G. Panico, Tricase, Italy, 10Ospedale Policlinico, Chieti, Italy, 11Istituto Burlo Garofolo, Trieste, Italy, 12University of Palermo, Palermo, Italy, 13Ospedale degli Infermi, Biella, Italy, 14Ospedale Pediatrico Bambino Gesù, Roma, Italy, 15Pediatrics, Università Cattolica Sacro Cuore, Rome, Italy, 16Claramalattia@Ospedale-Gaslini, Istituto Giannina Gaslini and University of Genova, Genova, Italy, 17Istituto G. Gaslini, Istituto Giannina Gaslini, Genova, Italy, 18Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy

    Background/Purpose In contrast with the numerous randomized controlled trials conducted in polyarticular or systemic juvenile idiopathic arthritis (JIA), little evidence-based information is available for oligoarticular…
  • Abstract Number: 312 • 2014 ACR/ARHP Annual Meeting

    Mutations in the MTHFR Gene Are Not Associated with Methotrexate Intolerance in Patients with Juvenile Idiopathic Arthritis

    Andrea Scheuern1, Nadine Fischer2, Johannes-Peter Haas1 and Boris Hugle1, 1German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, 2Research, German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany

    Background/Purpose:   Methotrexate (MTX) is the drug used most frequently in the therapy of juvenile idiopathic arthritis (JIA). However, long-term treatment in children frequently leads…
  • Abstract Number: 296 • 2014 ACR/ARHP Annual Meeting

    Countermeasures Against Methotrexate Intolerance in Juvenile Idiopathic Arthritis Instituted By Parents Show No Effect

    Andrea Scheuern1, Nadine Fischer2, Johannes-Peter Haas1 and Boris Hugle1, 1German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, 2Research, German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany

    Background/Purpose: Methotrexate (MTX) is the mainstay treatment in the therapy of children with juvenile idiopathic arthritis (JIA) and can lead to prolonged remission and improved…
  • Abstract Number: 792 • 2013 ACR/ARHP Annual Meeting

    Methotrexate Polyglutamates in Erythrocytes Are Associated With Lower Disease Activity in Juvenile Idiopathic Arthritis Patients

    Maja Bulatovic Calasan1, Ethan den Boer2, Maurits C.F.J. De Rotte3, S.J. Vastert4, Sylvia Kamphuis5, Robert De Jonge3 and Nico M. Wulffraat6, 1Paediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, 2Clinical Chemistry, Erasmus MC University Medical Center, Rotterdam, Netherlands, 3Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, 4Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, 5Pediatric Rheumatology, Eramus MC Sophia Children's Hospital, Rotterdam, Netherlands, 6Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose:  Methotrexate polyglutamates (MTX-PG) could be biomarkers of MTX response and adverse effects and could thus be used as a therapeutic drug monitoring (TDM) tool to steer tailor-made therapeutic…
  • Abstract Number: 297 • 2013 ACR/ARHP Annual Meeting

    Plasma Nicotinamide Phosphoribosyltransferase Correlates With Markers Of Inflammation and May Predict Early Therapeutic Response To Low-Dose Methotrexate In Juvenile Idiopathic Arthritis

    Ryan S. Funk1, Leon van Haandel1, Marcia Chan2, Lanny J. Rosenwasser2, Andrew Lasky3, Maria F. Ibarra4, Mark F. Hoeltzel5, S.Q. Ye6, J.S. Leeder1 and Mara L Becker7, 1Clinical Pharmacology and Medical Toxicology, Children's Mercy Hospital, Kansas City, MO, 2Pediatric Immunology Research, Children's Mercy Hospital, Kansas City, MO, 3Pediatrics Rheumatology, Children's Mercy Hospital, Kansas City, MO, 4Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, 5Rheumatology Section, Children's Mercy Hospital, Kansas City, MO, 6Medical Genetic Research, Children's Mercy Hospital, Kansas City, MO, 7Clinical Pharmacology and Rheumatology, Children's Mercy Hospital, Kansas City, MO

    Background/Purpose:   Despite a poor understanding of its biochemical role in the inflammatory process, nicotinamide phosphoribosyltransferase (NAMPT) has been implicated in a number of autoimmune…
  • Abstract Number: 268 • 2013 ACR/ARHP Annual Meeting

    Inflammatory Bowel Disease In Juvenile Idiopathic Arthritis Patients Upon Biologics

    Deborah Barthel1 and Gerd Horneff2, 1Paediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 2Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany

    Background/Purpose: Inflammatory bowel disease (IBD) is a matter of interest in patients with juvenile idiopathic arthritis (JIA) treated with biologics. Methods: Baseline demografics, clinical characteristics…
  • Abstract Number: 1159 • 2012 ACR/ARHP Annual Meeting

    Reasons and Predictors of Methotrexate Discontinuation in Children with JIA: Results From the Childhood Arthritis Prospective Study (CAPS)

    Suzanne Verstappen1, Lucy R. Wedderburn2, H. E. Foster3, Eileen Baildam4, Janet Gardner-Medwin5, Joyce Davidson5, Alice Chieng6, Wendy Thomson7 and Kimme L. Hyrich8, 1Arthritis Research UK Epidemiology Unit,, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, 2Rheumatology Unit , Institute of Child Health, University College London (UCL), London, United Kingdom, 3Paediatric Rheumatology, Newcastle Hospitals NHS Foundation Trust and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom, 4Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, 5Royal Hospital for Sick Children, Glasgow, United Kingdom, 6Manchester Children's Hospital, Manchester, United Kingdom, 7Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, Manchester, United Kingdom, 8Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom

    Background/Purpose: Methotrexate (MTX) is the DMARD of first choice in patients with juvenile idiopathic arthritis (JIA).  However, limited data is available on MTX survival, including…
  • Abstract Number: 1146 • 2012 ACR/ARHP Annual Meeting

    Choice of Systemic JIA Treatment Among Childhood Arthritis and Rheumatology Research Alliance (CARRA) Rheumatologists

    Jennifer E. Weiss1, Esi M. Morgan DeWitt2, Timothy Beukelman3, Laura E. Schanberg4, Rayfel Schneider5 and Yukiko Kimura6, 1Pediatric Rheumatology, Hackensack University Medical Center, Hackensack, NJ, 2Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4Pediatrics, Duke University Medical Center, Durham, NC, 5Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, Canada, 6Pediatric Rheumatology, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ

    Background/Purpose: Despite recent advances in identifying effective treatments for systemic Juvenile Idiopathic Arthritis (sJIA), many pediatric rheumatologists continue to use corticosteroids and methotrexate. The Childhood…
  • Abstract Number: 2654 • 2012 ACR/ARHP Annual Meeting

    Genome-Wide Association Study of Methotrexate Response Identifies Novel Genes in a Large Cohort of European Juvenile Idiopathic Arthritis Cases

    Joanna Cobb1, Erika Cule2, Halima Moncrieffe3, Edward Flynn4, Anne Hinks1, Fiona Patrick3, Laura Kassoumeri3, Simona Ursu5, Maja Bulatovic6, Marek Bohm7, Bertrand D. van Zelst8, Pavla Dolezalova9, Robert De Jonge8, Nico M. Wulffraat6, Stanton Newman10, Maria de Iorio11, Lucy R. Wedderburn3 and Wendy Thomson1, 1Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 2Department of Epidemiology and Biostatistics, Imperial College London, United Kingdom, 3Institute of Child Health, University College London, London, United Kingdom, 4Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom, 5Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, 6Paediatric Immunology, University Medical Centre Utrecht, Utrecht, Netherlands, 7First Faculty of Medicine and General Faculty Hospital, Prague, Czech Republic, 8Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, 9Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, 10School of Community & Health Sciences, City University London, London, United Kingdom, 11Department of Statistical Sciences, University College London, London, United Kingdom

    Background/Purpose: The drug methotrexate (MTX) is the first line treatment for many children with Juvenile Idiopathic Arthritis (JIA). Only 45% of children treated with MTX…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology